Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) is now available.
Jiangxi Rimag Group Co., Ltd. has announced the acquisition of Zhongya Diagnosis, a top-tier third-party imaging center in the province, through its subsidiary Hunan Rimag Medical Imaging Diagnosis Center Co., Ltd. The acquisition, valued at RMB29,500,000, aims to integrate Jiangxi Rimag’s standardized products and expand research collaborations with top-tier hospitals, enhancing the company’s market presence in Central China.
The most recent analyst rating on (HK:2522) stock is a Buy with a HK$21.41 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
More about Jiangxi Rimag Group Co., Ltd. Class H
Jiangxi Rimag Group Co., Ltd. is a leading medical group in China, specializing in medical imaging. It operates a medical imaging platform offering diversified imaging services and value across the entire medical imaging industry chain. The company primarily provides imaging center services, imaging solution services, and Rimag Cloud services.
Average Trading Volume: 4,692,848
Technical Sentiment Signal: Strong Sell
See more data about 2522 stock on TipRanks’ Stock Analysis page.